In general, the Asian markets have controlled the COVID-19 virus successfully outside of China, but its effect has still led to new developments and trends.
Across the continent, governments and hospitals are purchasing robotics systems from abroad as well as developing the technologies themselves.
With the exception of a few countries, Asia’s disease management industry is relatively unstructured.
While Western countries still have more medical device startups than the rest of the world, more new medtech startups are popping up in Asia than ever before.
Global sports medicine is predicted to grow to around $35 billion by 2022, with the Asian market growing at a compound annual growth rate of nearly 7 percent.
With the largest patient population in the world, the region has high growth potential over the next few years.